United Therapeutics has invested in the transplanted organ monitoring system developer as part of a collaboration agreement.
Tai Diagnostics, a US-based organ transplant aftercare technology spinout of Medical College of Wisconsin, closed a $10m series A round featuring biopharmaceutical company and strategic partner United Therapeutics on Monday.
Founded in 2015, Tai Diagnostics is working on a monitoring procedure for patients who have undergone an organ transplant.
Tai’s approach specifically identifies the transferred DNA that has been damaged, potentially acting as a more reliable indicator of organ rejection than the tissue biopsies often used today.
The technology is based on research by Michael Mitchell, a professor in cardiothoracic surgery, and Aoy Tomita-Mitchell, a professor of surgery and congenital heart surgery.
The funding will go to research and development ahead of clinical studies and an envisaged commercial launch. United and Tai have formed a collaboration agreement alongside the funding.
Tai Diagnostics has now raised $21m in total, the company said. That figure includes $8.2m in funding raised in a 2015 round led by Venture Investors, with participation from undisclosed backers.
– A version of this article first appeared on our sister site, Global Corporate Venturing.
